2.98
price down icon1.97%   -0.06
pre-market  Pre-market:  3.00   0.02   +0.67%
loading
Pliant Therapeutics Inc stock is traded at $2.98, with a volume of 1.70M. It is down -1.97% in the last 24 hours and down -73.42% over the past month. Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$3.04
Open:
$3.06
24h Volume:
1.70M
Relative Volume:
1.38
Market Cap:
$181.34M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.9644
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+14.40%
1M Performance:
-73.42%
6M Performance:
-76.25%
1Y Performance:
-82.09%
1-Day Range:
Value
$2.925
$3.22
1-Week Range:
Value
$2.43
$3.78
52-Week Range:
Value
$2.43
$18.00

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name
Name
Pliant Therapeutics Inc
Name
Phone
650-481-6770
Name
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Employee
166
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PLRX's Discussions on Twitter

Compare PLRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PLRX
Pliant Therapeutics Inc
2.98 181.34M 5.03M -185.41M -139.79M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.11 118.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.00 74.34B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
639.00 38.83B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.00 32.36B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
122.75 29.43B 3.30B -501.07M 1.03B -2.1146

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-10-25 Downgrade Canaccord Genuity Buy → Hold
Feb-10-25 Downgrade Citigroup Buy → Neutral
Feb-10-25 Downgrade H.C. Wainwright Buy → Neutral
Feb-10-25 Downgrade JP Morgan Overweight → Neutral
Feb-10-25 Downgrade Oppenheimer Outperform → Perform
Feb-10-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-10-25 Downgrade Wells Fargo Overweight → Equal Weight
Sep-09-24 Resumed Leerink Partners Outperform
Dec-08-23 Initiated Wells Fargo Overweight
May-18-23 Initiated Canaccord Genuity Buy
Apr-13-23 Initiated Robert W. Baird Outperform
Dec-14-22 Initiated Stifel Buy
Dec-07-22 Initiated JP Morgan Overweight
Sep-01-22 Initiated Citigroup Buy
Jul-20-22 Initiated SVB Leerink Outperform
May-25-22 Initiated Cantor Fitzgerald Overweight
Dec-10-21 Initiated Oppenheimer Outperform
Nov-24-21 Initiated RBC Capital Mkts Outperform
Nov-03-21 Initiated H.C. Wainwright Buy
Apr-20-21 Initiated BTIG Research Buy
Apr-05-21 Initiated Citigroup Buy
Jun-29-20 Initiated Citigroup Buy
Jun-29-20 Initiated Cowen Outperform
Jun-29-20 Initiated Needham Buy
Jun-29-20 Initiated Piper Sandler Overweight
View All

Pliant Therapeutics Inc Stock (PLRX) Latest News

pulisher
Feb 18, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - PR Newswire

Feb 18, 2025
pulisher
Feb 18, 2025

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire

Feb 18, 2025
pulisher
Feb 18, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Stockholders to Learn More About the Investigation - Markets Insider

Feb 18, 2025
pulisher
Feb 18, 2025

Pliant Therapeutics (PLRX) to Release Quarterly Earnings on Tuesday - MarketBeat

Feb 18, 2025
pulisher
Feb 17, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Investors to Inquire about Securities Investigation - Markets Insider

Feb 17, 2025
pulisher
Feb 17, 2025

Pliant Therapeutics chief business officer Hull sells $178,500 in stock - MSN

Feb 17, 2025
pulisher
Feb 16, 2025

Pliant Therapeutics' chief medical officer sells $206,973 in stock - MSN

Feb 16, 2025
pulisher
Feb 16, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Reach Out - Markets Insider

Feb 16, 2025
pulisher
Feb 16, 2025

What is HC Wainwright's Forecast for PLRX FY2029 Earnings? - MarketBeat

Feb 16, 2025
pulisher
Feb 15, 2025

Pliant Therapeutics (NASDAQ:PLRX) Price Target Lowered to $10.00 at Needham & Company LLC - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

Pliant Therapeutics' (PLRX) Market Perform Rating Reiterated at Oppenheimer - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

Pliant Therapeutics Initiates Outside Expert Panel to Review BEACON-IPF Trial Data - Defense World

Feb 15, 2025
pulisher
Feb 15, 2025

Pliant Therapeutics (NASDAQ:PLRX) Given Hold Rating at Canaccord Genuity Group - MarketBeat

Feb 15, 2025
pulisher
Feb 14, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Stockholders to Reach Out - Markets Insider

Feb 14, 2025
pulisher
Feb 14, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Stockholders to Connect - ACCESS Newswire

Feb 14, 2025
pulisher
Feb 14, 2025

Pliant Therapeutics' chief human resource officer sells $41,892 in stock - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

Pliant Thera lines up experts to review BEACON-IPF Phase IIb/III trial - The Pharma Letter

Feb 14, 2025
pulisher
Feb 14, 2025

Pliant Therapeutics stock hits 52-week low at $2.52 - MSN

Feb 14, 2025
pulisher
Feb 14, 2025

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Average Rating of "Hold" by Brokerages - MarketBeat

Feb 14, 2025
pulisher
Feb 14, 2025

Needham & Company LLC Issues Pessimistic Forecast for Pliant Therapeutics (NASDAQ:PLRX) Stock Price - MarketBeat

Feb 14, 2025
pulisher
Feb 13, 2025

Stifel maintains Pliant Therapeutics stock buy rating amid study pause By Investing.com - Investing.com Canada

Feb 13, 2025
pulisher
Feb 13, 2025

Sector Update: Health Care Stocks Mixed Thursday Afternoon -February 13, 2025 at 02:03 pm EST - Marketscreener.com

Feb 13, 2025
pulisher
Feb 13, 2025

Sector Update: Health Care Stocks Mixed Thursday Afternoon - TradingView

Feb 13, 2025
pulisher
Feb 13, 2025

Pliant Therapeutics Moves Forward With Expert Panel Following BEACON-IPF Trial Enrollment Pause - Nasdaq

Feb 13, 2025
pulisher
Feb 13, 2025

Sector Update: Health Care -February 13, 2025 at 01:45 pm EST - Marketscreener.com

Feb 13, 2025
pulisher
Feb 13, 2025

Stifel maintains Pliant Therapeutics stock buy rating amid study pause - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

Pliant stock jumps 28% on bexotegrast study update - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

Pliant stock jumps 28% on bexotegrast study update (PLRX:NASDAQ) - Seeking Alpha

Feb 13, 2025
pulisher
Feb 13, 2025

Pliant Therapeutics (NASDAQ:PLRX) Reaches New 52-Week LowWhat's Next? - MarketBeat

Feb 13, 2025
pulisher
Feb 13, 2025

Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis - The Manila Times

Feb 13, 2025
pulisher
Feb 13, 2025

Pliant Therapeutics Announces Next Steps Following DSMB - GlobeNewswire

Feb 13, 2025
pulisher
Feb 13, 2025

Pliant's IPF Drug Trial Hits Unexpected Hurdle: Expert Panel Called for Urgent Review - StockTitan

Feb 13, 2025
pulisher
Feb 13, 2025

What is HC Wainwright’s Estimate for PLRX FY2029 Earnings? - Defense World

Feb 13, 2025
pulisher
Feb 12, 2025

Pliant Therapeutics (NASDAQ:PLRX) Sets New 1-Year LowTime to Sell? - MarketBeat

Feb 12, 2025
pulisher
Feb 12, 2025

Pliant Therapeutics stock hits 52-week low at $2.52 By Investing.com - Investing.com Nigeria

Feb 12, 2025
pulisher
Feb 12, 2025

Pliant Therapeutics (NASDAQ:PLRX) Stock Price Down 8.7%Should You Sell? - MarketBeat

Feb 12, 2025
pulisher
Feb 12, 2025

Pliant Therapeutics, Inc. Company Investigated by the Portnoy Law Firm - GlobeNewswire

Feb 12, 2025
pulisher
Feb 12, 2025

Pliant pauses mid-stage trial for lung disease therapy - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

Canaccord Genuity cuts Pliant to hold on study setback - MSN

Feb 12, 2025
pulisher
Feb 12, 2025

Oppenheimer cuts Pliant Therapeutics stock rating amid trial pause - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

Pliant Therapeutics (NASDAQ:PLRX) Shares Down 8.7%Should You Sell? - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Pliant stock plunges 61% amid study pause, downgrades - MSN

Feb 11, 2025
pulisher
Feb 11, 2025

Citigroup Downgrades Pliant Therapeutics (PLRX) - MSN

Feb 11, 2025
pulisher
Feb 11, 2025

Pliant Therapeutics Pauses Enrollment and Dosing in BEACON-IPF TrialOn February 7, 2025, Pliant Therapeutics, Inc. (NASDAQ: PLRX) disclosed that, subsequent to a prespecified data review and recommendations made by the trial’s independent Data Saf - Defense World

Feb 11, 2025
pulisher
Feb 11, 2025

Canaccord Genuity cuts Pliant to hold on study setback (PLRX:NASDAQ) - Seeking Alpha

Feb 11, 2025
pulisher
Feb 11, 2025

Pliant Therapeutics downgraded to Neutral from Overweight at JPMorgan - Yahoo Finance

Feb 11, 2025
pulisher
Feb 11, 2025

Pliant Therapeutics (NASDAQ:PLRX) Downgraded by HC Wainwright to Neutral - Defense World

Feb 11, 2025
pulisher
Feb 11, 2025

Pliant Therapeutics (NASDAQ:PLRX) Lowered to Sector Perform Rating by Royal Bank of Canada - Defense World

Feb 11, 2025
pulisher
Feb 11, 2025

Pliant Therapeutics (NASDAQ:PLRX) Downgraded to “Equal Weight” Rating by Wells Fargo & Company - Defense World

Feb 11, 2025
pulisher
Feb 11, 2025

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of “Hold” from Brokerages - Defense World

Feb 11, 2025
pulisher
Feb 11, 2025

Pliant Therapeutics (NASDAQ:PLRX) Shares Up 6.7%Here's What Happened - MarketBeat

Feb 11, 2025

Pliant Therapeutics Inc Stock (PLRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$32.85
price up icon 1.51%
$81.36
price up icon 2.58%
$21.08
price down icon 1.36%
$372.83
price up icon 0.61%
biotechnology ONC
$238.11
price up icon 3.14%
$122.75
price up icon 2.44%
Cap:     |  Volume (24h):